Amarillo National Bank Sells 90 Shares of Danaher Co. (NYSE:DHR)

Amarillo National Bank lessened its position in shares of Danaher Co. (NYSE:DHR) by 5.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 1,675 shares of the conglomerate’s stock after selling 90 shares during the quarter. Amarillo National Bank’s holdings in Danaher were worth $418,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Tsfg LLC increased its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. Cape Investment Advisory Inc. purchased a new position in shares of Danaher in the 4th quarter worth approximately $25,000. BKM Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter valued at approximately $27,000. Redmont Wealth Advisors LLC purchased a new stake in Danaher during the 1st quarter valued at $30,000. Finally, Wetzel Investment Advisors Inc. bought a new stake in Danaher in the fourth quarter worth $29,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 0.2 %

NYSE:DHR traded down $0.41 during mid-day trading on Thursday, reaching $240.00. The company’s stock had a trading volume of 1,935,837 shares, compared to its average volume of 3,506,555. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $177.77 billion, a PE ratio of 40.68, a price-to-earnings-growth ratio of 3.68 and a beta of 0.83. The stock has a fifty day moving average of $255.67 and a 200-day moving average of $246.91. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $269.11.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same period last year, the business posted $2.36 EPS. The business’s revenue was down 2.6% compared to the same quarter last year. Equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of analyst reports. Jefferies Financial Group began coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective on the stock. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. HSBC raised Danaher from a “hold” rating to a “buy” rating and upped their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, TD Cowen increased their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $268.67.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock valued at $37,536,717 in the last 90 days. Insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.